Want to see IN:IPCALAB full AI Analyst Report?
IPCALAB Stock Chart & Stats
₹1762.70
₹14.90(0.85%)
At close: 4:00 PM EDT
₹1762.70
₹14.90(0.85%)
Day’s Range― - ―
52-Week Range₹1,252.95 - ₹1,941.40
Previous CloseN/A
Volume119.64K
Average Volume (3M)6.78K
Market Cap
₹443.18B
Enterprise Value₹417.40K
Total Cash (Recent Filing)₹11.98B
Total Debt (Recent Filing)₹8.09B
Price to Earnings (P/E)38.9
Beta0.18
Next Earnings
Aug 13, 2026EPS Estimate
12.16Next Dividend Ex-DateN/A
Dividend Yield0.23%
Share Statistics
EPS (TTM)44.98
Shares Outstanding253,659,230
10 Day Avg. Volume6,645
30 Day Avg. Volume6,776
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)5.04
Price to Sales (P/S)4.21
P/FCF Ratio83.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)55.29
Revenue Forecast (FY)₹107.74B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetA very low debt-to-equity (~0.10 in 2026) provides durable financial flexibility, lowering refinancing and interest risk. This conservative leverage supports investment in capacity, R&D or compliance actions after inspections, and cushions earnings volatility over the next 2–6 months and beyond.
Vertical Integration (APIs + FDFs)Owning API manufacturing alongside finished-dosage production creates a structural edge: it reduces third-party supply dependence, supports gross-margin resilience through captive consumption and allows price/volume flexibility. That integration sustainably improves cost competitiveness and product continuity.
Scale With Solid ProfitabilityMaterial scale and maintained mid-teens gross and double-digit net margins indicate underlying operational strength. Even with slower top-line expansion, this level of profitability supports reinvestment and resilience across markets, making earnings less sensitive to single-market disruptions.
Bears Say
Margin CompressionSustained margin compression signals structural headwinds—costs, mix shifts, or pricing pressure—that reduce return on capital. If persistent, it erodes cash available for growth, weakens ROE and limits the company's ability to fund capex or absorb regulatory compliance costs without margin recovery.
Slowing Revenue GrowthA slowdown to roughly 3.1% growth indicates weakening top-line momentum versus prior periods. Slower revenue expansion constrains operating leverage benefits, reduces headroom for margin recovery, and limits internal funding for new product launches or geographic expansion over the medium term.
Moderate Free-cash-flow ConversionFree-cash-flow conversion below historical norms (~0.43x of net income) shows working-capital and capex demands absorb a large portion of earnings. That limits balance-sheet optionality, slows deleveraging or shareholder returns, and constrains the pace of strategic investments over the coming months.
IPCA Laboratories Limited News
IPCALAB FAQ
What was IPCA Laboratories Limited’s price range in the past 12 months?
IPCA Laboratories Limited lowest stock price was ₹1252.95 and its highest was ₹1941.40 in the past 12 months.
What is IPCA Laboratories Limited’s market cap?
IPCA Laboratories Limited’s market cap is ₹443.18B.
When is IPCA Laboratories Limited’s upcoming earnings report date?
IPCA Laboratories Limited’s upcoming earnings report date is Aug 13, 2026 which is in 3 days.
How were IPCA Laboratories Limited’s earnings last quarter?
IPCA Laboratories Limited released its earnings results on May 29, 2026. The company reported ₹11.8 earnings per share for the quarter, beating the consensus estimate of ₹10.074 by ₹1.726.
Is IPCA Laboratories Limited overvalued?
According to Wall Street analysts IPCA Laboratories Limited’s price is currently Overvalued.
Does IPCA Laboratories Limited pay dividends?
IPCA Laboratories Limited pays a Annually dividend of ₹6 which represents an annual dividend yield of 0.23%. See more information on IPCA Laboratories Limited dividends here
What is IPCA Laboratories Limited’s EPS estimate?
IPCA Laboratories Limited’s EPS estimate is 12.16.
How many shares outstanding does IPCA Laboratories Limited have?
IPCA Laboratories Limited has 253,659,230 shares outstanding.
What happened to IPCA Laboratories Limited’s price movement after its last earnings report?
IPCA Laboratories Limited reported an EPS of ₹11.8 in its last earnings report, beating expectations of ₹10.074. Following the earnings report the stock price went down -3.753%.
Which hedge fund is a major shareholder of IPCA Laboratories Limited?
Currently, no hedge funds are holding shares in IN:IPCALAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IPCA Laboratories Limited
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Technical Analysis
Ajanta Pharma Limited
―
Emcure Pharmaceuticals Limited
―
―
Neuland Laboratories Ltd.
―
Wockhardt Limited
―